RNV Stock Chart & Stats
AU$0.08
-AU$0.02(-9.09%)
At close: 4:00 PM EST
AU$0.08
-AU$0.02(-9.09%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.22
Previous CloseN/A
Volume539.06K
Average Volume (3M)68.42K
Market Cap
AU$15.96M
Enterprise ValueAU$11.65M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding173,504,780
10 Day Avg. Volume73,245
30 Day Avg. Volume68,419
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Renerve Limited News
RNV FAQ
What was Renerve Limited’s price range in the past 12 months?
Renerve Limited lowest share price was AU$0.06 and its highest was AU$0.22 in the past 12 months.
What is Renerve Limited’s market cap?
Renerve Limited’s market cap is AU$15.96M.
When is Renerve Limited’s upcoming earnings report date?
Renerve Limited’s upcoming earnings report date is Mar 04, 2027 which is in 127 days.
How were Renerve Limited’s earnings last quarter?
Renerve Limited released its earnings results on Aug 27, 2026. The company reported -AU$0.017 earnings per share for the quarter.
Is Renerve Limited overvalued?
According to Wall Street analysts Renerve Limited’s price is currently Overvalued.
Does Renerve Limited pay dividends?
Renerve Limited does not currently pay dividends.
What is Renerve Limited’s EPS estimate?
Renerve Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renerve Limited have?
Renerve Limited has 173,504,780 shares outstanding.
What happened to Renerve Limited’s price movement after its last earnings report?
Renerve Limited reported an EPS of -AU$0.017 in its last earnings report. Following the earnings report the stock price went up 5.479%.
Which hedge fund is a major shareholder of Renerve Limited?
Currently, no hedge funds are holding shares in AU:RNV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Renerve Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RNV Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$34.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.00%
12-Months-Change
Fundamentals
Return on Equity
-133.13%
Trailing 12-Months
Asset Growth
-26.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Renerve Limited
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; and amniotic tissue product ranges used to aid the healing of wounds under the Empliq brand. In addition, it provides Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand that are in development phase. The company was incorporated in 2016 and is headquartered in Northcote, Australia.





